Abstract
There is currently little information regarding the role of active smoking in predisposing to SARS-CoV-2 infection. This retrospective case series includes 441 patients with confirmed Covid-19, who were consecutively admitted between March 5 and March 31, 2020, at a tertiary referral center in Parma, Northern Italy, with laboratory-confirmed COVID-19. 273 (62%) patients were males. Median age was 71 y/o, 156 patients (35%) died during hospitalization and 285 (65%) were discharged because clinically healed. 21 patients (5%) were active smokers and 44 (10%) were ex-smokers, while 376 (85%) were non-smokers. Male sex, history of prior cardiovascular disease, D-dimer and C-reactive protein were significantly more prevalent or higher in the subgroup of 156 patients who died during hospital stay, compared with 285 patients discharged alive. Active smokers were only 21, this number corresponding to less than 5% prevalence of active smokers, which is disproportionately low compared with the 24% prevalence of smokers in the general Italian population (p<0.001). The very low prevalence of smokers in our COVID-19 cohort seemingly replicates the findings that can be extracted from descriptive tables in Chinese reports and also in the recent US reports from New York City. The current study is useful since it suggests that smokers may carry some type of protective mechanism from symptomatic SARS-CoV-2 infection, although this should definitely be confirmed in specifically-designed, controlled studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no funding.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De identified data can be made available upon reasonable request by other investigators.
